IRD
Opus Genetics, Inc.
NASDAQ: IRD · HEALTHCARE · BIOTECHNOLOGY
$4.99
-6.90% today
Updated 2026-05-08
Market cap
$356.30M
P/E ratio
—
P/S ratio
25.10x
EPS (TTM)
$-0.80
Dividend yield
—
52W range
$1 – $6
Volume
0.9M
Opus Genetics, Inc. (IRD) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-3.59M | $-6.80M | $-19.37M | $14.31M | $-1.11M | $-25.58M | $-35.25M |
| Capital expenditures | $25000.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation | $3000.00 | $8000.00 | $4000.00 | $4000.00 | $6000.00 | $10000.00 | — |
| Stock-based comp | $308000.00 | $1.51M | $1.91M | $1.81M | $3.51M | $3.36M | $3.40M |
| Free cash flow | $-3.62M | $-6.80M | $-19.37M | $14.31M | $-1.11M | $-25.58M | $-35.25M |
| Investing cash flow | $-25000.00 | $539000.00 | $-100000.00 | — | — | $1.21M | — |
| Financing cash flow | $4.70M | $21.12M | $27.61M | $3.79M | $8.98M | $4.19M | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — |